Similar outcomes have been documented in treatment with IV tPA with BP variability.
Short-term memory and levels of fatigue improved, but no benefit for depression was observed.
Those treated with DBS had a 50% lower risk of worsening motor symptoms compared to those on drug therapy alone.
Risk appeared to be correlated with RLS disease duration.
As many as 50% of neurotoxic chemotherapy patients experience CPN.
Those with the lowest B12 levels performed worse on cognitive and motor outcomes.
The drug helped to significantly improve social functioning, medication effects, and seizure worry in patients.
Cerebral microbleeds are a marker of vascular burden and should be aggressively pursued with treatment and preventive care.
The disorders react similarly to basal ganglia deep brain stimulation.
Neurology Advisor Articles
- FDA Approves Aimovig for Migraine Prevention
- Prediction Algorithm Stratifies ICH Patients at Risk for Hematoma Expansion
- Sports-Related Concussion Outcomes Predicted With Serum Neurofilament Light
- FDA: Lamotrigine Linked to Potentially Life-Threatening Adverse Reaction
- Psychological Therapies May Help Older Adults With Chronic Pain
- Amyloid Positivity Increases Risk for Cognitive Impairment in Dementia-Free Patients
- Valproic Acid-Related Adverse Fetal Outcomes May Be Linked to Placental Effects
- Risk of Dementia Up for Older Adults With Lowest Wealth
- Language Used in Medical Record Can Affect Patient Care
- Mortality in Alzheimer Disease Not Strongly Associated With Antipsychotics